EM1811E "Proton Pump Inhibitors: Balancing the Benefits and Risks of Long-Term Use" (IM GR-110218)
Purpose & Overview
The purpose of this presentation is to provide information on the history of pulmonary hypertension discoveries that led to targeted therapies for patients, and to discuss new recent work on metabolism in pulmonary vascular disease.
UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.
At the conclusion of this activity, the participant should be able to:
- Know the mechanism of action and pharmacokinetics of PPI therapy
- List the indications for long-term PPI use
- Know which reported adverse effects have likely causality versus those with weak association, unproven causality
- Know the common reasons for PPI misuse
- Understand a general approach to PPI de-escalation
Chenlu (Maria) Tian, M.D.
Department of Internal Medicine
Division of Digestive & Liver Diseases
Dr. Chenlu Tian is an assistant professor in the Department of Digestive and Liver Diseases at UT Southwestern Medical Center. In addition to housestaff teaching, Dr. Tian has a clinical interest in quality improvement and promoting patient health education. In 2016, she implemented an electronic consultation platform for the Department of Digestive and Liver Diseases within the electronic medical records system of Parkland Health Systems to improve primary provider access to specialist input. She continues to be a provider for e-consultation. Through her practice, she has noticed increased primary care provider concern regarding use of PPIs in recent years as this class of medication has come under closer scrutiny for reports of various adverse effects. However, PPIs are also highly effective in the treatment of various acid-related upper GI disorders. The purpose of this presentation is to address the benefits of long-term PPI use in a defined set of indications, examine the evidence behind reported potential risks, and finally discuss how to mitigate the risks including an approach to de-escalation of therapy.
- 1.00 AMA